Invasive pneumococcal disease in Australia: 2013 and 2014
DOI:
https://doi.org/10.33321/cdi.2025.49.038Keywords:
Australia, invasive pneumococcal disease, communicable disease surveillance, epidemiology, annual reportAbstract
In Australia, there were 1,552 cases (6.7 per 100,000 population per year) of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System (NNDSS) in 2013, and 1,564 cases (6.7 per 100,000 population per year) in 2014. The non-age standardised rate of IPD in Indigenous Australians was six times the rate of IPD in non-Indigenous Australians in both 2013 and 2014. Following the July 2011 introduction of the 13-valent pneumococcal conjugate vaccine (13vPCV) to the National Immunisation Program (NIP), the overall rate of IPD in children aged less than 5 years decreased from 19.8 per 100,000 population per year in 2011 to 12.5 per 100,000 population per year in 2013. In 2014 there was a slight increase in the overall rate of IPD in children aged less than 5 years to 14.1 per 100,000 population per year in 2014. In both 2013 and 2014, the rate of IPD caused by serotypes included 23-valent pneumococcal polysaccharide vaccine (23vPPV) declined in Indigenous adults aged 50 years or older (40.5 per 100,000 population per year and 35.2 per 100,000 population per year, respectively) after displaying a gradual increase between 2002 and 2012. Rates of IPD in non-Indigenous adults aged 65 years or older caused by serotypes included in the 23vPPV also declined in both 2013 and 2014 (9.5 per 100,000 population per year and 8.3 per 100,000 population per year, respectively) compared to 2011 (11.8 per 100,000 population per year). There were 134 deaths attributable to IPD in 2013 (a case fatality rate of 8.6%) and 118 in 2014 (a case fatality rate of 7.5%).
Downloads
References
World Health Organization (WHO). Pneumococcal Disease. [Internet.] Geneva: WHO. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/pneumococcal-disease.
Dey A, Knox S, Wang H, Beard FH, McIntyre PB. Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2008–2011. Commun Dis Intell Q Rep. 2016;40(Suppl):S1–70.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in pneumococcal vaccination practice in Australia. Sydney: NCIRS; July 2018. Available from: http://www.ncirs.org.au/sites/default/files/2018-11/Pneumococcal-history-August-2018.pdf.
Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Canberra: Australian Government Department of Health and Aged Care, ATAGI; 18 May 2022. Available from: https://immunisationhandbook.health.gov.au/about-the-handbook.
Pennington K, Enhanced Invasive Pneumococcal Disease Surveillance Working Group. Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.40.
Communicable Diseases Network Australia (CDNA). Invasive pneumococcal disease case definition. Canberra: Australian Government Department of Health and Aged Care, CDNA; 12 March 2004. Available from: https://www.health.gov.au/resources/publications/invasive-pneumococcal-disease-surveillance-case-definition.
Australian Bureau of Statistics (ABS). 3101.0 - Australian Demographic Statistics, Jun 2017. [Webpage.] Canberra: ABS; 14 December 2017. Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3101.0Main+Features1Jun%202017.
ABS. 3238.0.55.001 – Estimates of Aboriginal and Torres Strait Islander Australians, June 2011. [Webpage.] Canberra: ABS; 30 August 2013. Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3238.0.55.001Main+Features1June%202011.
Hull B, Hendry A, Dey A, Beard F, Brotherton J, McIntyre P. Immunisation coverage annual report, 2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.11.
Bareja C, Toms C, Lodo K, de Kluyver R, Enhanced Invasive Pneumococcal Disease Surveillance Working Group. Invasive pneumococcal disease in Australia, 2009 and 2010. Commun Dis Intell Q Rep. 2015;39(2):E265–79.
Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi: https://doi.org/10.1016/S1473-3099(14)70822-9.
Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017–26. doi: https://doi.org/10.1128/CVI.00062-10.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi: https://doi.org/10.1016/S2213-2600(16)00052-7.
Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. doi: https://doi.org/10.1542/peds.2009-3027.
Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74. doi: https://doi.org/10.1093/cid/ciy129.
Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V et al. Long-term impact of a "3 + 0" schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002–2014. Clin Infect Dis. 2017;64(2):175–83. doi: https://doi.org/10.1093/cid/ciw720.
Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127–31. doi: https://doi.org/10.1016/j.vaccine.2011.09.112.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. doi: https://doi.org/10.1016/S1473-3099(14)71081-3.
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. doi: https://doi.org/10.1016/S1473-3099(15)70044-7.
Zimmermann P, Perrett KP, Berbers G, Curtis N. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine. Arch Dis Child. 2019;104(7):680–4. doi: https://doi.org/10.1136/archdischild-2018-316254.
Blyth CC, Jayasinghe S, Andrews RM. A rationale for change: an increase in invasive pneumococcal disease in fully vaccinated children. Clin Infect Dis. 2020;70(4):680–3. doi: https://doi.org/10.1093/cid/ciz493.
Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135–43. doi: https://doi.org/10.1093/cid/ciy920.
Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221(8):1361–70. doi: https://doi.org/10.1093/infdis/jiz178.
De Wals P, Lefebvre B, Deceuninck G, Longtin J. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. Vaccine. 2018;36(3):421–6. doi: https://doi.org/10.1016/j.vaccine.2017.11.054.
Haggie S, Fitzgerald DA, Pandit C, Selvadurai H, Robinson P, Gunasekera H et al. Increasing rates of pediatric empyema and disease severity with predominance of serotype 3 S. pneumonia: an Australian single-center, retrospective cohort 2011 to 2018. Pediatr Infect Dis J. 2019;38(12):e320–5. doi: https://doi.org/10.1097/INF.0000000000002474.
Toms C, de Kluyver R, Enhanced Invasive Pneumococcal Disease Surveillance Working Group. Invasive pneumococcal disease in Australia, 2011 and 2012. Commun Dis Intell Q Rep. 2016;40(2):E267–84.
Cook H, Markey P, O'Hare S, Smith HV, Tindall H, Yip TW et al. Lengthy widespread outbreak of serotype-1 invasive pneumococcal disease shows protection with the 10-valent conjugate vaccine and increased pneumonia complications. [Conference proceedings.] 8th International Symposium on Pneumococci and Pneumococcal Diseases, 11–15 March 2012; Iguacu Falls, Brazil.
Lai JY, Cook H, Yip TW, Berthelsen J, Gourley S, Krause V et al. Surveillance of pneumococcal serotype 1 carriage during an outbreak of serotype 1 invasive pneumococcal disease in central Australia 2010–2012. BMC Infect Dis. 2013;13:409. doi: https://doi.org/10.1186/1471-2334-13-409.
Zivich PN, Grabenstein JD, Becker-Dreps S, Webber DJ. Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review. Pneumonia (Nathan). 2018;10:11. doi: https://doi.org/10.1186/s41479-018-0055-4.
Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006–2010. Commun Dis Intell Q Rep. 2013;37(Suppl):S1–95.
Meder KN, Jayasinghe S, Beard F, Dey A, Kirk M, Cook H et al. Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalizations in Indigenous and non-Indigenous Australians. Clin Infect Dis. 2020;70(12):2607–15. doi: https://doi.org/10.1093/cid/ciz731.
Ioannides S, Beard F, Larter N, Clark K, Wang H, Hendry A et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.36.
Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C et al. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine. 2015;33(48):6666–74. doi: https://doi.org/10.1016/j.vaccine.2015.10.089.
Einsiedel LJ, Fernandes LA, Woodman RJ. Racial disparities in infection-related mortality at Alice Springs Hospital, Central Australia, 2000–2005. Med J Aust. 2008;188(10):568-71. doi: https://doi.org/10.5694/j.1326-5377.2008.tb01791.x.
ABS. 4727.0.55.001 – Australian Aboriginal and Torres Strait Islander Health Survey: First Results, Australia, 2012-13. [Webpage.] Canberra: ABS; 27 November 2013. Available from: https://www.abs.gov.au/ausstats/abs@.nsf/mf/4727.0.55.001.
Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for Indigenous populations. Epidemiol Rev. 2006;28(1):71–80. doi: https://doi.org/10.1093/epirev/mxj005.
Krause VL, Reid SJ, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994–1998. Med J Aust. 2000;173(S2):S27–31. doi: https://doi.org/10.5694/j.1326-5377.2000.tb139410.x.
Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland, 1999-2004. Med J Aust. 2006;184(3):118–21. doi: https://doi.org/10.5694/j.1326-5377.2006.tb00149.x.
Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD et al. The changing epidemiology of invasive pneumococcal disease in Aboriginal and non-Aboriginal Western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis. 2010;50(11):1477–86. doi: https://doi.org/10.1086/652440.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455–63. doi: https://doi.org/10.1056/NEJMoa051642.
Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl 3):16–20. doi: https://doi.org/10.1111/j.1469-0691.2009.02726.x.
Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. 2017;24(3):e361–9. doi: https://doi.org/10.1097/MJT.0000000000000551.
Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2017: second Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2017. Available from: https://www.safetyandquality.gov.au/publications-and-resources/resource-library/aura-2017-second-australian-report-antimicrobial-use-and-resistance-human-health.
Oftadeh S, Gidding HF, Gilbert GL. Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates. Epidemiol Infect. 2013;141(9):1797–806. doi: https://doi.org/10.1017/S095026881200218X.
Published
How to Cite
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
